Binge
Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027, a report published by Ken Research
gives a thorough analysis on the market opportunities for the therapeutics of
binge eating disorder, and gives a forecast of the same to 2027. It discussed
the current market landscape for BED therapeutics in the seven major markets:
US, France, Germany, Italy, Spain, UK and Japan. Comparing the available
options with each other, as well as across the global front; the report also
talks about the required needs in the BED treatment and its management. The
report contains insights on the drivers and barriers in the market.
First identified in 1959 by Albert Hunkard,
Binge Eating Disorder is a condition wherein the subject consumes large amount
of food at irregular intervals- often secretly. The condition which affects so
many and is known to have a link to obesity, was surprisingly recognised as an
official distinct disorder in as late as 2013. With the official recognition,
the awareness about the disorder has been increasing. However, due to many
reasons, an effective identification and diagnosis of the condition is on a low
scale.
Classified along with conditions like anorexia
nervosa and bulimia nervosa, binge eating disorder is the most common occurring
eating disorder in USA. It generally occurs amongst the adolescents and adults.
The concern around the disorder is not just the obesity but the root causes
often associated with it. Experts understand that BED generally occurs
alongside depression, anxiety disorder or substance abuse or even lifestyle
stress. Hence, a proper diagnosis and treating the root cause becomes important
in the treatment.
The problem faced by practitioners is
identification of the disorder. In many cases binging behaviour is triggered
only by comfort food that results in just a case of overeating that is not
regular. The catch is to find a pattern not just in the eating habits but the
behavioural aspects as well. In many cases of BED, patients are caught in a
viscous cycle of disorders. There is an inability to understand whether it’s
the depression that results into binge eating or the binge eating is making
them depressed. This can sometimes lead to excessive diet or purging, again
resulting into depression. Hence, a combined treatment that includes a
psychiatrist, therapists and nutritionists is required.
Cognitive Behavioural Theory or CBT is
regarded as the first in line treatment for BED. Another alternative treatment
is Pharmacotherapy. But this line of treatment is still into development, with
only one pharmacotherapy to have received approved label expansion from FDA.
With increasing awareness about the disorder, more number of cases are coming
to light. Researchers and practitioners are trying to develop new drugs and therapies
to cure the same. With increased connectivity and access to information,
patients from different countries have also started to look for the treatment
options.
The companies covered in the concerned report
are: Shire, Sunovion, Novo Nordisk, H. Lundbeck, Eli Lilly, Orexigen
Therapeutics, Vivus, Jazz Pharmaceuticals
For more information, click on the
link below:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91
9015378249